Achillion Pharmaceuticals’ (NASDAQ:ACHN) danicopan received FDA breakthrough therapy designation for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In PNH, the complement system destroys red blood cells in...
The Safety Review Committees overseeing Salarius Pharmaceuticals’ (NASDAQ:SLRX) Phase 1/2 clinical study of Seclidemstat in Ewing sarcoma and the Phase 1 study of Seclidemstat in patients with advanced solid tumors...
BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) appointed immunology expert, Cara Haymaker, to its scientific advisory board, effective immediately. In addition, Dr. Bill Williams, president and CEO, has been selected to...
Mateon Therapeutics’ (NASDAQ:MATN) OT-101 received FDA pediatric disease designation for the treatment of diffuse intrinsic pontine glioma (DIPG). DIPG is a rare pediatric brainstem tumor that has a very low survival...
Ovid Therapeutics (NASDAQ:OVID) reported positive initial data from its Phase 2 study of soticlestat, a cholesterol 24-hydroxylase inhibitor, in patients with rare developmental and epileptic encephalopathies (DEE). ...
Aldeyra Therapeutics’ (NASDAQ:ALDX) ADX-2191 received FDA fast track designation for the prevention of proliferative vitreoretinopathy (PVR). PVR is an inflammatory disorder of the retina that leads to severe retinal...
Ocular Therapeutix (NASDAQ:OCUL) has dosed the first patients in its Phase 3 efficacy trial of DEXTENZA for the treatment of symptoms of allergic conjunctivitis (AC). DEXTENZA is a corticosteroid that is FDA-approved...
BTIG initiated coverage of NeuBase Therapeutics (NASDAQ:NBSE) with a “buy” rating and $15 price target. The stock closed at $6.55 on Sept. 23. NeuBase has developed a modular antisense peptide nucleic acid (PNA)...
Closely-held Soricimed reported that The University of Texas MD Anderson Cancer Center (MDACC) has begun dosing the first cohort of three late-stage pancreatic cancer patients in its investigator-initiated trial of SOR...
Zenabis Global (TSX:ZENA) has received the licensing of Phase 2C – Part 2 at its Zenabis Atholville site in New Brunswick for an additional 3,000 kg of licensed annual cultivation capacity of cannabis. The amendment...
BeyondSpring’s (NASDAQ:BYSI) poster with findings from its Study 106 has been accepted for presentation at this year’s European Society for Medical Oncology Congress in Barcelona on Sept. 28. In Study 106, BeyondSpring...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Aerie Pharmaceuticals’ (NASDAQ:AERI) marketing authorization application (MAA) for Rhokiinsa solution. The...